Compound muscle action potential and mot
β
Aga Lewelt; Kristin J. Krosschell; Charles Scott; Ai Sakonju; John T. Kissel; Th
π
Article
π
2010
π
John Wiley and Sons
π
English
β 191 KB
## Abstract Reliable outcome measures that reflect the underlying disease process and correlate with motor function in children with SMA are needed for clinical trials. Maximum ulnar compound muscle action potential (CMAP) data were collected at two visits over a 4β6βweek period in children with SM